Fresenius Medical Care North America (FMCNA) has announced an investment in BioIntelliSense, a Denver-based company that is developing a medical grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights. FMCNA is committed to bringing its expertise in advanced analytics and artificial intelligence to the development and deployment of this system in cooperation with BioIntelliSense. The aim is to jointly create clinical pathways that can alert clinicians to the need for early intervention, potentially preventing patients from complications and, thus, reducing unnecessary as well as costly hospitalizations. The investment, therefore, supports Fresenius Medical Care’s strategic goal to improve monitoring, interventions and outcomes for patients living with kidney disease and other chronic illnesses in order to increase their quality of life.
Fresenius Kabi launches Levothyroxine Sodium Injection in the U.S. It is the first, and only, pre-mixed solution of this medication currently available in the U.S.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, is expanding its clinical research activities. Frenova Renal Research (Frenova), previously a Fresenius Medical Care North America subsidiary, will now offer its services worldwide and will be integrated into the new Global Medical Office headed by Dr. Frank Maddux, Chief Medical Officer.
Frenova offers services for the clinical development of medicines and medical products in the field of kidney research. This offering, previously limited to North America, will now be linked with the corresponding services of Fresenius Medical Care’s Europe, Middle East and Africa (EMEA) and Latin America regions and bundled under Frenova. This will enable the company to draw on a network of more than 550 researchers at over 350 locations.
“Frenova is active at the intersection of clinical research and patient care,” said Dr. Maddux. “No other provider of clinical development services understands the medical needs of people living with kidney disease as well as we do. By making this expertise available worldwide, we will enable a faster, more efficient development of medications and other products. This is an additional, important building block for improving their quality of life.”
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.
June 28, 2019
Amsterdam, The Netherlands
Kepler Cheuvreux One Stop Shop Amsterdam
Fresenius Medical Care, the world’s largest provider of dialysis products and services, yesterday successfully placed bonds with an aggregate principal amount of USD 500 million. The bonds have a maturity of 10 years and an annual coupon of 3.750%. The issue price is 98.461%, resulting in a yield of 3.938%.
The proceeds will be used for general corporate purposes, including the refinancing of outstanding indebtedness.
Application will be made for admission to trading of the bonds on the regulated market of the Luxembourg Stock Exchange.
Disclaimer
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein have not been and will not be registered under U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement has been prepared on the basis that any offer of Notes in any Member State of the European Economic Area (EEA) which has implemented the Prospectus Directive (2003/71/EC), as amended (each, a Relevant Member State) will be made pursuant to an exemption under the Prospectus Directive, as implemented in that Relevant Member State, from the requirement to publish a prospectus for offers of securities. Fresenius Medical Care AG & Co. KGaA has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius Medical Care AG & Co. KGaA or any other person to publish or supplement a prospectus for such offer.
This announcement is directed at and/or for distribution in the United Kingdom only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons are referred to herein as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.
This announcement contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this announcement. In furnishing our website address in this announcement, we do not intend to incorporate any information on our website into this announcement.
Neostigmine is now available in the company’s Simplist® ready-to-administer prefilled syringes, expanding the company´s analgesia and anesthesia portfolio.
-
Download image ... a traditional gingko, the tree of life, in front of Fresenius’ new EK3 headquarters building. Mayor Alexander Hetjes of Bad Homburg welcomed Fresenius Medical Care’s support for organ transplantation: “I’m very happy when companies Download Image (JPG 29.69 MB) -
![]()
After a raffle among employee raised €770 the company announced it would increase that amount 10-fold, for a total donation of €7,700 to Kinderhilfe Organtransplantation. Download Image (JPG 4.32 MB) -
![]()
Mayor Alexander Hetjes of Bad Homburg and Dr. Katarzyna Mazur-Hofsäß, Fresenius Medical Care's Chief Executive Officer for Europe, Middle East and Africa, together planted ... Download Image (JPG 19.69 MB) -
![]()
... a traditional gingko, the tree of life, in front of Fresenius’ new EK3 headquarters building. Download Image (JPG 7.73 MB)
"Give life a chance" was the motto under which Fresenius Medical Care, the world’s largest provider of dialysis products and services, informed employees in Bad Homburg yesterday about organ donation. Individuals not only need to be well informed and carefully consider whether or not they wish to make an organ donation: Above all, they need to make a decision.
"Fresenius Medical Care supports organ transplantation,” said Dr. Katarzyna Mazur-Hofsäß, Fresenius Medical Care's Chief Executive Officer for Europe, Middle East and Africa. “For our patients with chronic kidney disease, a future worth living includes hope for a transplant, and that is exactly what we are preparing our patients for in our dialysis clinics. We want to educate and inform today, because during their lifetimes many people do not make a decision about a possible donation of their organs.”
Mayor Alexander Hetjes of Bad Homburg welcomed Fresenius Medical Care’s support for organ transplantation. “I’m very happy when companies in Bad Homburg also get involved in debates about social issues,” the mayor said. “To me it’s important to talk with many people about organ donation, so that we can all be better informed when making this very personal decision.”
Two organ donor recipients reported on their experiences via video, and medical information was explained to the employees by Dr. Anja Brückel of the German Organ Transplantation Foundation. "In Germany, more than 9,000 seriously ill people are waiting for a donor organ,” Dr. Brückel said. “For them, transplantation is the only way to survive or significantly improve their quality of life. However, this is only possible if people are willing to donate their organs. That’s why it is important to address the issue of organ donation during one’s lifetime, make close relatives aware of the decision, and fill out an organ donor card.”
The foundation made organ donation cards available to interested employees. Mayor Hetjes, Dr. Mazur-Hofsäß and Dr. Brückel together planted a traditional gingko, the tree of life, in front of Fresenius’ new EK3 headquarters building. And after a raffle among employees raised €770 the company announced it would increase that amount 10-fold, for a total donation of €7,700 to Kinderhilfe Organtransplantation, a German charity that supports children undergoing transplants and their families.
June 11, 2019
Rancho Palos Verdes, USA
Goldman Sachs Annual Global Healthcare Conference
June 11 – 12, 2019